Compounds

1. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:

Wherein

Y is selected from hydrogen, hydroxyl, —NH 2 , —NH—C 1-4 -alkyl, —NH-halo-C 1-4 -alkyl and C 1-4 -alkoxy;

Z is selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy halo-C 1-4 -alkoxy, CONH 2 , SO 2 NH 2 , —NH 2 , —NH—C 1-4 -alkyl, and —NH-halo-C 1-4 -alkyl;

R 1 is a phenyl ring or a 5 or 6-membered heteroaryl ring, optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 ,

NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , and —NR 6 S(O) 2 R 5 ;

W is a phenyl ring or a 5 or 6-membered heteroaryl ring, optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , —SO 2 NR 4A R 4B , and —NR 6 S(O) 2 R 5 ;

R 2 is —B-Q-[R 3 ] n or —B—R 3 , wherein n=1, 2, 3, or 4;

B is a bond, —O—, —NR 5 —, —C(O)—, or —C 1-3 -alkylene-;

Q is a saturated or partially unsaturated 3-7 membered heterocyclic or C 3-7 -cycloalkyl ring;

when R 2 is —B-Q-[R 3 ] n , R 3 is selected from hydrogen, halogen, cyano, amino, hydroxyl, oxo, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)amino-C 1-4 -alkyl, —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —NR 6 S(O) 2 R 5 , —S(O) 2 R 5 , C 1-4 -alkyl-NR 6 C(O)OR 5 , —C 1-4 -alkyl-NR 6 C(O)NR 4A R 4B , amino-C 1-4 -alkoxy-C 1-4 -alkyl-, (amino-C 1-4 -alkyl)-amino-C 1-4 -alkyl-, —C 1-4 -alkyl-C(O)R 5 , —OC(O)R 5 , —C 1-4 -alkyl-C(O)OR 5 , —C 1-4 -alkyl-C(O)NR 4A R 4B , —C 1-4 -alkyl-NR 6 C(O)NR 4A R 4B , 3-7 membered heterocyclyl, C 3-7 -cycloalkyl, 3-7 membered heterocyclyl-C 1-4 -alkyl-, (3-7 membered heterocyclyl-C 1-4 -alkyl)-amino-C 1-4 -alkyl-, phenyl-C 1-4 -alkyl, and 5 or 6-membered heteroaryl-C 1-4 -alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)amino-C 1-4 -alkyl, —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , and —NR 6 S(O) 2 R 5 ;

when R 2 is —B—R 3 , R 3 is selected from —NH 2 , C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)amino-C 1-4 -alkyl,

—NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A1 R 4B , —C(O)R 5 , —NR 6 S(O) 2 R 5 , 3-7 membered heterocyclyl-C 1-4 -alkyl-, phenyl-C 1-4 -alkyl, and heteroaryl-C 1-4 -alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)amino-C 1-4 -alkyl, —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , and —NR 6 S(O) 2 R 5 , provided that when R 2 is —B—R 3 , and B is a bond and R 3 is —C(O)R 5 , then R 5 is not hydrogen;

R 4A , R 4B and R 5 are each independently selected from hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)-amino-C 1-4 -alkyl, C 1-4 alkoxy-C 1-4 alkyl, 3-7 membered heterocyclyl-, 3-7 membered heterocyclyl-C 1-4 -alkyl-, C 1-4 -alkyl-NR 6 C(O)OR 5 , C 1-4 -alkyl-NR 6 C(O)R 5 , (3-7 membered heterocyclyl-C 1-4 -alkyl)-amino-C 1-4 -alkyl-, C 3-7 -cycloalkyl, and 5 or 6-membered heteroaryl-C 1-4 -alkyl-, wherein the alkyl part of the 5 or 6-membered heteroaryl-C 1-4 -alkyl group is optionally substituted on one or more carbon atoms with a group selected from halogen, C 1-4 alkyl, and C 3-7 -cycloalkyl, or one of the carbon atoms of the same alkyl part is substituted with two C 1-4 alkyl substituents which together with the carbon atom to which they are attached form a C 3-7 -cycloalkyl ring, or

R 4A and R 4B together with the nitrogen to which they are attached form a 4-7 membered cyclic amino group optionally substituted by one or more substituents selected from oxo, halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl, halo-C 1-4 -alkoxy, —C(O)NR 4A R 4B , —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, —NHhalo-C 1-4 -alkyl, —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , and C 3-7 -cycloalkyl;

unless otherwise specified the 3-7 membered heterocyclyl, or the heterocyclyl part of the 3-7 membered heterocyclyl-C 1-4 -alkyl- or (3-7 membered heterocyclyl-C 1-4 -alkyl)-amino-C 1-4 -alkyl-group is optionally substituted with one or more substituents selected from C 1-4 -alkyl, —C(O)OR 5 , —C(O)R 5 , —C(O)NR 4A R 4B ,

—NR 4A R 4B , —C 1-4 -alkyl-C(O)NR 4A R 4B , and C 1-4 alkoxy-C 1-4 alkyl; and

R 4A1 is selected from C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di(C 1-4 -alkyl)amino-C 1-4 -alkyl and C 1-4 alkoxy-C 1-4 alkyl; or

R 4A1 and R 4B together with the nitrogen to which they are attached form a 4-7 membered cyclic amino group optionally substituted by one or more substituents selected from oxo, halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 alkoxy-C 1-4 alkyl-, halo-C 1-4 -alkoxy, —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, —NHhalo-C 1-4 -alkyl, —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , and C 3-7 -cycloalkyl; and

R 6 is hydrogen or C 1-4 -alkyl.

2. A compound according to claim 1 wherein Y is H.

3. A compound according to claim 1 wherein Z is H.

4. A compound according to claim 1 wherein R 1 is a phenyl ring or a 6-membered heteroaryl ring, optionally substituted with one or more substituents selected from halogen, C 1-4 -alkyl, and halo-C 1-4 -alkyl.

5. A compound according to claim 1 wherein R 1 is a phenyl ring or a 6-membered heteroaryl ring, optionally substituted with one or more substituents selected from F, Cl, and CH 3 .

6. A compound according to claim 1 wherein W is a 5 or 6-membered heteroaryl ring optionally substituted with one or more substituents selected from halogen, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, and

—NR 4A R 4B .

7. A compound according to claim 1 wherein W is selected from pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, imidazolyl, pyrrolyl, tetrazolyl, oxazolyl, thiazolyl, 1,2,3-triazolyl, and 1,2,4-triazolyl, any of which is optionally substituted according to claim 1 .

8. A compound according to claim 1 wherein R 2 is -Q-[R 3 ] n .

9. A compound according to claim 1 wherein Q is a 7-membered saturated or partially unsaturated 7-membered heterocyclic or cycloalkyl ring.

10. A compound according to claim 1 wherein Q is a homomorpholine ring.

11. A compound according to claim 1 wherein Q is a saturated or partially unsaturated 5 or 6 membered heterocyclic or cycloalkyl ring.

12. A compound according to claim 1 wherein Q is selected from tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, cyclopentyl, cyclopropyl, and cyclohexyl.

13. A compound according to claim 1 wherein R 3 is selected from hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, 3-7 membered heterocyclyl, 3-7 membered heterocyclyl-C 1-4 -alkyl-, and

—C(O)NR 4A R 4B .

14. A compound according to claim 1 wherein Q is piperidinyl and R 3 is —CONH 2 .

15. A compound according to claim 1 wherein R 2 is selected from the list of further R 2 groups as defined in the specification.

16. A compound according to claim 1 wherein R 2 is —B—R 3 , B is —C 1-3 -alkylene-, and —R 3 is —NR 4A R 4B .

17. A compound according to claim 16 wherein R 4A and R 4B are each independently selected from hydrogen and C 1-4 -alkyl.

18. A compound according to claim 1 wherein W is an imidazolyl ring optionally substituted as in claim 1 , and wherein the imidazolyl ring is connected to the pyrrolopyridine core via an imidazoly ring carbon atom.

19. A compound according to claim 1 selected from:

4-[2-(6-Aminopyridin-3-yl)-1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(pyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(6-methoxypyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(2-methoxypyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-[6-(morpholin-4-yl)pyridin-3-yl]-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(pyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-pyrazol-3-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1-methyl-1H-imidazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-pyrazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-imidazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;

4-[1-(4-Chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;

5-[1-(4-Chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-amine;

{[1-(4-Chlorophenyl)-2-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]methyl}dimethyl amine;

{[1-(4-Chlorophenyl)-2-(pyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]methyl}dimethyl amine; and

4-[1-(4-Chlorophenyl)-2-(2H-1,2,3,4-tetrazol-5-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine;

and pharmaceutically acceptable salts thereof.

20. A pharmaceutical composition comprising a compound according to claim 1 , and one or more suitable excipients.